Sarepta names Michael Severino its new chief executive

Andrew covers the biopharma business, scientific analysis, and public well being throughout the continent. You possibly can attain Andrew confidentially on Sign at drewqjoseph.71.

Sarepta Therapeutics, the bruised maker of Duchenne muscular dystrophy remedies, on Monday named Michael Severino, previously the CEO of Tessera Therapeutics, as its new chief government, beginning Tuesday. 

Severino is changing Doug Ingram, who introduced earlier this yr that he deliberate to retire after main the biotech for almost a decade. Throughout his tenure, the corporate bought three Duchenne remedies accepted, however has confronted ongoing questions on how efficient they’re and run into regulatory scrutiny over the protection of its gene remedy. The corporate’s share value has tanked from the place it was at first of 2025.

Severino might be tasked with steadying Sarepta’s enterprise and making ready it for competitors, with next-generation merchandise heading towards potential approval that might substitute Sarepta’s personal exon-skippers. Different Duchenne gene therapies are additionally shifting towards the market.